Biogen
BIIB
1,008 hedge funds and large institutions have $36.1B invested in Biogen in 2023 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 321 increasing their positions, 363 reducing their positions, and 84 closing their positions.
15% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 84
3% more capital invested
Capital invested by funds: $35B → $36.1B (+$1.14B)
1% more funds holding
Funds holding: 1,001 → 1,008 (+7)
0.92% less ownership
Funds ownership: 88.51% → 87.59% (-0.92%)
7% less call options, than puts
Call options by funds: $555M | Put options by funds: $599M
5% less funds holding in top 10
Funds holding in top 10: 19 → 18 (-1)
12% less repeat investments, than reductions
Existing positions increased: 321 | Existing positions reduced: 363
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$1.01B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$264M |
| 3 |
Amundi
Paris,
France
|
+$181M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$109M |
| 5 |
JP Morgan Chase
New York
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$668M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$286M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$157M |
| 4 |
D.E. Shaw & Co
New York
|
-$145M |
| 5 |
Millennium Management
New York
|
-$140M |
BIIB Hedge Fund Activity: Q2 2023 in Review
1,008 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2023, worth a combined $36.1B — up 3.2% from $35B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new BIIB positions and 84 closed out — a net gain of 13 holders — while 321 added to existing stakes and 363 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $1.01B. The largest seller was Envestnet Asset Management, cutting an estimated $668M.
- 1,008 institutional investors held Biogen (BIIB) as of Q2 2023, up from 1,001 in Q1 2023.
- Funds reported $36.1B of Biogen stock for Q2 2023, up 3.2% quarter-over-quarter.
- 97 funds opened new Biogen positions in Q2 2023 and 84 closed out, a net change of +13 holders.
- The largest Biogen buyer in Q2 2023 was T. Rowe Price Investment Management, an estimated $1.01B added.
- The largest Biogen seller in Q2 2023 was Envestnet Asset Management, an estimated $668M sold.
Based on aggregated 13F filings for Q2 2023.